Dr. Kaliyaperumal is an accomplished senior research and development leader with over 20 years of experience in immunology, molecular biology, pre-clinical research, early external technology evaluation and translational sciences.
Prior to joining ReCode Therapeutics in 2021, he served as a research fellow at Eli Lilly where he led early pre-clinical development of biologics risk assessments and mitigation. Prior to Lilly, Dr. Kaliyaperumal had positions of increasing responsibility, including as a principal scientist at Amgen and provided technical leadership in immunology and immunogenicity of various therapeutic products in research and clinical development, along with submission of IND and BLA applications for key autoimmune disease portfolio assets. Prior to Amgen, Dr. Kaliyaperumal served as the lead scientist at Powderject vaccines (acquired by Chiron vaccines) and oversaw the immunology and bioanalytical development of DNA vaccines for infectious disease and other oncology targets.
Dr. Kaliyaperumal received his Ph.D. in Immunology from the National Institute of Immunology, India. He was a post-doctoral fellow at the University of Chicago and an assistant professor at Northwestern University. Dr. Kaliyaperumal has published over 40 peer reviewed journal articles, has contributed more than 15 book chapters and holds a U.S. patent.